Altimmune (ALT) News Today → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free ALT Stock Alerts $7.72 +0.56 (+7.82%) (As of 05/9/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineINVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Altimmune Inc. to Contact Law Firmprnewswire.com - May 9 at 5:51 PMAltimmune (NASDAQ:ALT) Trading Up 8.1%marketbeat.com - May 9 at 2:02 PMALT Stock Earnings: Altimmune Beats EPS for Q1 2024msn.com - May 9 at 12:41 PMAltimmune, Inc: Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Updatefinanznachrichten.de - May 9 at 8:56 AMAltimmune Announces First Quarter 2024 Financial Results and Provides a Business Updateglobenewswire.com - May 9 at 7:00 AMROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ALTprnewswire.com - May 8 at 10:30 PMAltimmune earnings: here's what Wall Street expectsmarkets.businessinsider.com - May 8 at 3:48 PMGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investorstmcnet.com - May 8 at 3:48 PMALTIMMUNE, INC. (NASDAQ:ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadlinestockhouse.com - May 8 at 9:10 AMAltimmune (ALT) Scheduled to Post Earnings on Thursdayamericanbankingnews.com - May 8 at 5:34 AMClass Action Filed Against Altimmune, Inc. (ALT) Seeking Recovery for Investors – Contact Levi & Korsinsky LLPmsn.com - May 8 at 12:44 AMALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!prnewswire.com - May 7 at 10:17 PMINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investorsbusinesswire.com - May 7 at 8:51 PMThe Law Offices of Frank R. Cruz Announces Investigation of Altimmune, Inc. (ALT) on Behalf of Investorsbusinesswire.com - May 7 at 3:06 PMROSEN, A LEADING LAW FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ALTbusinesswire.com - May 7 at 2:15 PMAmgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominancecnbc.com - May 7 at 11:33 AMJim Cramer Calls Nutanix 'The Perfect Enterprise Software Company For The Moment'benzinga.com - May 7 at 9:24 AMAltimmune to Participate at Two Upcoming Investor Conferencesglobenewswire.com - May 7 at 7:30 AMPomerantz Law Firm Announces the Filing of a Class Action Against Altimmune, Inc. and Certain Officers - ALTprnewswire.com - May 6 at 6:50 PMDEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmunestockhouse.com - May 6 at 6:22 PMAmgen stock rallies 13% on GLP-1 weight-loss drug updatemsn.com - May 3 at 6:52 PMAltimmune (ALT) Set to Announce Earnings on Thursdaymarketbeat.com - May 3 at 9:45 AMAltimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024globenewswire.com - May 2 at 7:30 AMAltimmune (NASDAQ:ALT) Shares Up 9.9%marketbeat.com - May 1 at 4:49 PMAltimmune to Participate at Two Upcoming Conferencesglobenewswire.com - May 1 at 7:30 AMBriumvi’s Market Share Growth and TG Therapeutics’ Strong Financial Outlook Justify Buy Ratingmarkets.businessinsider.com - April 30 at 6:47 PMPeering Into Altimmune's Recent Short Interestbenzinga.com - April 30 at 1:47 PMAltimmune (NASDAQ:ALT) Downgraded to Neutral at Guggenheimamericanbankingnews.com - April 30 at 5:32 AMDeutsche Bank, Daqo New Energy And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionmsn.com - April 29 at 9:37 AMAltimmune (NASDAQ:ALT) Downgraded by Guggenheimmarketbeat.com - April 29 at 7:32 AMShort Interest in Altimmune, Inc. (NASDAQ:ALT) Rises By 14.9%marketbeat.com - April 29 at 7:13 AMAltimmune Statement on the Passing of Dr. Stephen Harrisonglobenewswire.com - April 25 at 5:24 PMAltimmune (NASDAQ:ALT) Shares Down 5.3% marketbeat.com - April 24 at 6:15 PM3 Speculative Weight Loss Drug Stocks to Bet On for Big Gainsinvestorplace.com - April 24 at 6:33 AMAltimmune (NASDAQ:ALT) Shares Up 6.5%marketbeat.com - April 22 at 4:46 PMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?marketbeat.com - April 22 at 6:05 AMWegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (ALT)marketbeat.com - April 22 at 6:05 AMGlobal COVID-19 Testing Strategic Analysis Report 2024: Market to Reach $5.8 Billion by 2030 from $19.9 Billion in 2023finance.yahoo.com - April 19 at 12:28 AMAltimmune, Inc. (ALT)finance.yahoo.com - April 18 at 6:22 AMAltimmune (NASDAQ:ALT) Shares Down 7% marketbeat.com - April 15 at 5:31 PMBuy Altimmune's Potential Market Disruption With Pemvidutideseekingalpha.com - April 12 at 1:10 PM3 Biotech Stocks to Turn $5,000 Into $1 Million: April 2024investorplace.com - April 11 at 12:24 PMForget Viking Therapeutics. Here's 1 Weight-Loss Stock to Keep Your Eyes on Instead.fool.com - April 9 at 6:45 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?marketbeat.com - April 9 at 6:08 AMCan Altimmune get its GLP-1 Drug to Market Before Cash Rush Out? marketbeat.com - April 9 at 6:07 AMAltimmune (NASDAQ:ALT) Shares Down 5.2% marketbeat.com - April 8 at 11:59 AMTimelo Investment Management Inc. Grows Stock Position in Altimmune, Inc. (NASDAQ:ALT)marketbeat.com - April 6 at 6:39 PMHC Wainwright Weighs in on Altimmune, Inc.'s Q1 2024 Earnings (NASDAQ:ALT)marketbeat.com - April 4 at 8:48 AMAltimmune (NASDAQ:ALT) Stock Price Down 8.1% After Analyst Downgrademarketbeat.com - April 2 at 10:27 AMThe 3 Best Biotech Stocks to Buy in April 2024investorplace.com - April 1 at 9:09 PM Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. >> Register right here ALT Media Mentions By Week ALT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.070.37▲Average Medical News Sentiment ALT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼214▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Korro Bio News KalVista Pharmaceuticals News Fulcrum Therapeutics News Neurogene News Larimar Therapeutics News Arbutus Biopharma News Shattuck Labs News Verve Therapeutics News Astria Therapeutics News Applied Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 5/9/2024 by MarketBeat.com Staff From Our Partners1970’s computer coder Issues Shocking AI WarningInvestorPlaceThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeUrgent Nvidia WarningAltimetryThe Crypto 9-5 Escape PlanCrypto 101 Media348 million Americans lives to END as we know it?The Oxford Club Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.